Some bacteria become resistant to many antibiotics.
These resistant bacteria are much more difficult to treat.
Treatment may be longer and more costly.
Mortality is increased.
Worldwide antimicrobial
(bacterial and fungal)
resistance contributed to
5 million deaths in 2019
Chronic soft tissue infections typically have multiple bacteria. Resistant bacteria are especially difficult to treat. Overuse of a new antibiotic could lead to bacteria developing resistance to the new antibiotic.
MRSA (methicillin-resistant S. aureus) is a bacteria that is highly resistant to many antibiotics.
It is a serious problem in hospitals.
Patients who are carriers of MRSA (nose, skin) or
have a MRSA infection are placed in strict isolation in the hospital.
MRSA is common in soft tissue infections. Treatment requires weeks of IV antibiotics.
MRSA infection leads to
increased morbidity, mortality,
length of stay and a
significant increase in cost of care.
IV Antibiotic
Treatment
A special type of plastic catheter is inserted into a vein and remains in place for weeks.
There is a risk of contamination and developing a second infection from the catheter.
Only compliant patients can go home with the catheter.
Sonofii technology resolved over 80% of MRSA soft tissue infections —
most with a single treatment.
Our dual localized treatment reduced the need for weeks of IV antibiotics.
Resolution of the infection accelerated wound healing.